Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Omacor[trademark]; Editorial: "...clear benefit in terms of patient survival have also been shown after supplementation with fish oils...following MI - a benefit which was shown to be in addition to statin, [beta]-blocker, ACE-inhibitor and aspirin therapy." Disease Overview: "Long-term clinical management for secondary prevention post-MI should include modification, cardiac rehabilitation and pharmacological intervention." Drug Review: "Omacor displays a wide range of cardiovascular effects including the ability to increase HRV, to prevent cardiac arrhythmia and fibrillation, to prevent atherosclerosis and to decrease blood pressure." Improving Practice: "Post-MI patients who ate oily fish, rich in marine omega-3 polyunsaturated fats, twice a week, had a 29 per cent reduction in all-cause mortality and a 33 per cent reduction in CHD mortality at 2 years."
